Who are Add Glimepiride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amaryl, Glucotrol, Micronase, Aglicid, Diabinese, oral hypoglycemic agents.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/add-glimepiride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Add Glimepiride — Competitive Intelligence Brief

Add Glimepiride (Add Glimepiride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea. Area: Diabetes.

marketed Sulfonylurea Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Add Glimepiride (Add Glimepiride) — Samsung Medical Center. Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Add Glimepiride TARGET	Add Glimepiride	Samsung Medical Center	marketed	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
Amaryl	GLIMEPIRIDE	Sanofi	marketed	Sulfonylurea [EPC]	Sulfonylurea receptor 1, Kir6.2	1995-01-01
Glucotrol	GLIPIZIDE	Pfizer	marketed	Sulfonylurea [EPC]	Sulfonylurea receptor 1, Kir6.2	1984-01-01
Micronase	glibenclamide	Sanofi	marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1984-01-01
Aglicid	TOLBUTAMIDE		marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1961-01-01
Diabinese	CHLORPROPAMIDE	Pfizer	marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1958-01-01
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)

Recent regulatory actions (last 90 days)

2026-03-04 — Glucotrol · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea class)

Merck Sharp & Dohme LLC · 6 drugs in this class
Pfizer · 2 drugs in this class
Sanofi · 2 drugs in this class
Janssen Research & Development, LLC · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Servier Affaires Médicales · 1 drug in this class
The George Institute · 1 drug in this class
· 1 drug in this class
University of Glasgow · 1 drug in this class
GRADE Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Add Glimepiride — Competitive Intelligence Brief. https://druglandscape.com/ci/add-glimepiride. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab